title: Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide.
abstract: Treatment of malignant paraganglioma remains a challenge with an overall 5-year survival rate between 34 and 60%. Systemic treatment is recommended in case of unresectable malignant paraganglioma. Recent advances in molecular biology provided rationale to use antiangiogenic agents in this setting. Metronomic cyclophosphamide could be efficient by antiangiogenic effect and immune stimulation with a good safety profile. Here, we report two cases of malignant paraganglioma in frail and symptomatic patients, achieving a long-term clinical benefit with such regimen, after progression or toxicity with sunitinib.
authors.affiliation: Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Gillon
authors.forename: Yann
authors.initials: Y
authors.lastname: Godbert
authors.forename: Charles
authors.initials: C
authors.lastname: Dupin
authors.forename: Virginie
authors.initials: V
authors.lastname: Bubien
authors.forename: Antoine
authors.initials: A
authors.lastname: Italiano
authors.forename: Guilhem
authors.initials: G
authors.lastname: Roubaud
mesh_terms: D059250:Administration, Metronomic; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010235:Paraganglioma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide
keywords: antiangiogenic agents; cyclophosphamide; malignant paraganglioma; metronomic chemotherapy